

SANOFI-AVENTIS  
Form 6-K  
October 28, 2005

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**  
□□□□□□□□  
**FORM 6-K**  
**REPORT OF FOREIGN PRIVATE ISSUER  
PURSUANT TO RULE 13a-16 OR 15d-16  
UNDER THE SECURITIES EXCHANGE ACT OF 1934**  
□□□□□□□□  
For the month of October 2005

Commission File Number: 001-31368

**SANOFI-AVENTIS**  
(Translation of registrant's name into English)

174, avenue de France, 75013 Paris, FRANCE  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F    Form 40-F  
x                    o

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): \_\_\_\_\_

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): \_\_\_\_\_

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes o                    No x

If  Yes  marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-\_\_\_\_\_

On October 28, 2005, sanofi-aventis issued the press release attached hereto as Exhibit 99.1, which is incorporated herein by reference.

**Exhibit List**

<u>Exhibit No.</u>	<u>Description</u>
Exhibit 99.1	Press Release dated October 28, 2005, concerning FDA review period for Exubera®.

2

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: October 28, 2005

SANOFI-AVENTIS

By: /s/ Patricia Kodyra  
Name: Patricia Kodyra  
Title: Associate Vice President  
Financial and Securities Law

3

---

**Exhibit List**

<u>Exhibit No.</u>	<u>Description</u>
Exhibit 99.1	Press Release dated October 28, 2005, concerning FDA review period for Exubera®.

4

---